Join
Live feed
·
INSIDERFilingvia Quantisnow
G1 Therapeutics Inc. logo

Chief Business Officer Avagliano Mark was granted 20,600 shares and returned 236,610 shares to the company, closing all direct ownership in the company (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GTHX (G1 Therapeutics Inc.) and more on Quantisnow.